Letermovir Prophylaxis for Cytomegalovirus Infection in Adult Allogeneic Stem Cell Transplantation: A Retrospective Analysis From a Lower-Middle-Income Country. (PubMed, Cureus) - Feb 24, 2026 - "No statistically significant differences were observed between innovator and bioequivalent letermovir formulations with respect to safety or CMV outcomes. Availability of a cost-effective bioequivalent formulation may substantially expand access to CMV prophylaxis, supporting improved transplant outcomes in high-burden LMICs."
Journal • Retrospective data • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Transplantation
|
|
Anindita Paul; Anusha Swaminathan; Ashutosh Panda; Kapil Chahal; Neha Rastogi; Nikhil M Kumar; Onyeaghala Chizaram; Rachit Agrawal; Rahul Bhargava; Shrinidhi Nathany; Suyash Bharat; Swati Bhayana; Vikas Dua
|